Full Press Release Details
| Alkermes Contacts: | ||
| For Investors: | Sandy Coombs +1 781 609 6377 | |
| For Media: | Katie Joyce +1 781 249 8927 |
Alkermes plc Reports Second Quarter 2025 Financial Results
Second Quarter Revenues of $390.7 Million
GAAP Net Income of $87.1 Million and Diluted GAAP Earnings per Share of $0.52
Company Reiterates 2025 Financial Expectations
Alkermes to Present Detailed Vibrance-1 Results at Upcoming World Sleep Congress
DUBLIN, July 29, 2025 Alkermes plc (Nasdaq: ALKS) today reported financial results for the second quarter of 2025.
Our second quarter results reflect strong performance across all three of our proprietary products and robust profitability and cash flow generation, said Richard Pops, Chief Executive Officer of Alkermes. Against the backdrop of solid financial performance, the recently announced positive topline results from Vibrance-1, our phase 2 study of alixorexton (ALKS 2680) in narcolepsy type 1, were an important milestone in the development program and underscore the differentiated features of alixorexton. These data also highlight the potential of orexin 2 receptor agonists to transform the treatment of narcolepsy. As we prepare to initiate a global phase 3 program, we look forward to sharing detailed results from Vibrance-1 at the upcoming World Sleep Congress and topline results from our Vibrance-2 study in patients with narcolepsy type 2 this fall.
Key Financial Highlights
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||
| (In millions) | 2025 | 2024 | 2025 | 2024 | |||||
| Total Revenues | $ | 390.7 | $ | 399.1 | $ | 697.2 | $ | 749.5 | |
| Total Proprietary Net Sales | $ | 307.2 | $ | 269.3 | $ | 551.7 | $ | 502.8 | |
| VIVITROL | $ | 121.7 | $ | 111.9 | $ | 222.7 | $ | 209.5 | |
| ARISTADA i | $ | 101.3 | $ | 86.0 | $ | 174.8 | $ | 164.9 | |
| LYBALVI | $ | 84.3 | $ | 71.4 | $ | 154.3 | $ | 128.4 |
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||
| (In millions) | 2025 | 2024 | 2025 | 2024 | |||||
| GAAP Net Income From Continuing Operations | $ | 87.1 | $ | 94.7 | $ | 109.6 | $ | 133.6 | |
| GAAP Net Income (Loss) From Discontinued Operations | $ | $ | (3.3) | $ | $ | (5.4) | |||
| GAAP Net Income | $ | 87.1 | $ | 91.4 | $ | 109.6 | $ | 128.2 | |
| EBITDA From Continuing Operations | $ | 101.6 | $ | 118.6 | $ | 124.3 | $ | 170.1 | |
| EBITDA From Discontinued Operations | $ | $ | (3.9) | $ | $ | (6.4) | |||
| EBITDA | $ | 101.6 | $ | 114.7 | $ | 124.3 | $ | 163.7 | |
| Adjusted EBITDA | $ | 126.5 | $ | 135.3 | $ | 172.1 | $ | 217.1 |
-Revenues for the quarter were $84.3 million.
-Revenues and total prescriptions for the quarter grew 18% and 22%, respectively, compared to the second quarter of 2024.
-Revenues for the quarter were $101.3 million.
-Revenues for the quarter grew 18% compared to the second quarter of 2024.
-During the quarter, the company recorded ARISTADA revenue of approximately $11.0 million related to gross-to-net favorability, primarily driven by Medicaid utilization adjustments.
-Revenues for the quarter were $121.7 million.
-Revenues for the quarter grew 9% compared to the second quarter of 2024.
-During the quarter, the company recorded VIVITROL revenue of approximately $9.0 million related to gross-to-net favorability, primarily driven by Medicaid utilization adjustments.
Manufacturing & Royalty Revenues
-VUMERITY manufacturing and royalty revenues for the quarter were $39.4 million.
-Royalty revenues from XEPLION , INVEGA TRINZA /TREVICTA and INVEGA HAFYERA /BYANNLI for the quarter were $30.3 million.
Key Operating Expenses
Please see Note 1 below for details regarding discontinued operations.
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||
| (In millions) | 2025 | 2024 | 2025 | 2024 | |||||
| R&D Expense Continuing Operations | $ | 77.4 | $ | 59.6 | $ | 149.2 | $ | 127.3 | |
| R&D Expense Discontinued Operations | $ | $ | 3.9 | $ | $ | 6.4 | |||
| SG&A Expense Continuing Operations | $ | 170.8 | $ | 168.1 | $ | 342.6 | $ | 347.9 | |
| SG&A Expense Discontinued Operations | $ | $ | $ | $ |
At June 30, 2025, the company recorded cash, cash equivalents and total investments of $1.05 billion, compared to $916.2 million at March 31, 2025.
Financial Expectations for 2025
Alkermes reiterates its financial expectations for 2025, as set forth in its press release dated Feb. 12, 2025.
Notes and Explanations
1.The company determined that upon the separation of its former oncology business, completed on Nov. 15, 2023, the oncology business met the criteria for discontinued operations in accordance with Financial Accounting Standards Board Accounting Standards Codification 205, Discontinued Operations. Accordingly, the accompanying selected financial information has been updated to present the results of the oncology business as discontinued operations for the three and six months ended June 30, 2024.
Alkermes will host a conference call and webcast presentation with accompanying slides at 8:00 a.m. ET (1:00 p.m. BST) on Tuesday, July 29, 2025, to discuss these financial results and provide an update on the company. The webcast may be accessed on the Investors section of Alkermes' website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. In addition, a replay of the conference call may be accessed by visiting Alkermes' website.
Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. For more information, please visit Alkermes' website at www.alkermes.com.
Non-GAAP Financial Measures
This press release includes information about certain financial measures that are not prepared in accordance with generally accepted accounting principles in the U.S. (GAAP), including EBITDA and Adjusted EBITDA. These non-GAAP measures are not based on any standardized methodology prescribed by GAAP and are not necessarily comparable to similar measures presented by other companies.
EBITDA represents earnings before interest, tax, depreciation and amortization. Adjusted EBITDA excludes share-based compensation expense in addition to the components of EBITDA from earnings.
The company's management and board of directors utilize these non-GAAP financial measures to evaluate the company's performance. The company provides these non-GAAP financial measures of the company's performance to investors because management believes that these non-GAAP financial measures, when viewed with the company's results under GAAP and the accompanying reconciliations, are useful in identifying underlying trends in ongoing operations. However, EBITDA and Adjusted EBITDA are not measures of financial performance under GAAP and, accordingly, should not be considered as alternatives to GAAP measures as indicators of operating performance. Further, EBITDA and Adjusted EBITDA should not be considered measures of the company's liquidity.
A reconciliation of GAAP to non-GAAP financial measures has been provided in the tables included in this press release.
Note Regarding Forward-Looking Statements
Certain statements set forth in this press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: the company's expectations concerning its future financial and operating performance, business plans or prospects; and the company's expectations regarding development plans, activities and timelines for, and the potential therapeutic and commercial value of, alixorexton (formerly referred to as ALKS 2680). The company cautions that forward-looking statements are inherently uncertain. The forward-looking statements are neither promises nor guarantees and they are necessarily subject to a high degree of uncertainty and risk. Actual performance and results may differ materially from those expressed or implied in the forward-looking statements due to various risks and uncertainties. These risks and uncertainties include, among others: whether the company is able to achieve its financial expectations; clinical development activities may not be initiated or completed on expected timelines or at all; the results of the company's development activities may not be positive, or predictive of future results
from such activities, results of future development activities or real-world results; the company's products or product candidates could be shown to be ineffective or unsafe; the U.S. Food and Drug Administration (FDA) or regulatory authorities outside the U.S. may not agree with the company's regulatory approval strategies or may make adverse decisions regarding the company's products; potential changes in the cost, scope and duration of the company development programs; the unfavorable outcome of arbitration, litigation, or other proceedings or disputes related to the company's products or products using the company's proprietary technologies; the company and its licensees may not be able to continue to successfully commercialize their products or support revenue growth from such products; there may be a reduction in payment rate or reimbursement for the company's products or an increase in the company's financial obligations to government payers; the company's products may prove difficult to manufacture, be precluded from commercialization by the proprietary rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; and those risks and uncertainties described under the heading Risk Factors in the company's Annual Report on Form 10-K for the year ended Dec. 31, 2024 and in subsequent filings made by the company with the U.S. Securities and Exchange Commission (SEC), which are available on the SEC's website at www.sec.gov. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by law, the company disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release.
VIVITROL is a registered trademark of Alkermes, Inc.; ARISTADA , ARISTADA INITIO and LYBALVI are registered trademarks of Alkermes Pharma Ireland Limited, used by Alkermes, Inc. under license; BYANNLI , INVEGA HAFYERA , INVEGA TRINZA , TREVICTA and XEPLION are registered trademarks of Johnson & Johnson or its affiliated companies; and VUMERITY is a registered trademark of Biogen MA Inc., used by Alkermes under license.
| Alkermes plc and Subsidiaries | ||||||||
| Selected Financial Information (Unaudited) | ||||||||
| Condensed Consolidated Statements of Operations - GAAP | Three Months Ended | Three Months Ended | ||||||
| (In thousands, except per share data) | June 30, 2025 | June 30, 2024 | ||||||
| Revenues: | ||||||||
| Product sales, net | $ | 307,235 | $ | 269,273 | ||||
| Manufacturing and royalty revenues | 83,422 | 129,858 | ||||||
| Total Revenues | 390,657 | 399,131 | ||||||
| Expenses: | ||||||||
| Cost of goods manufactured and sold | 49,460 | 61,472 | ||||||
| Research and development | 77,370 | 59,649 | ||||||
| Selling, general and administrative | 170,849 | 168,113 | ||||||
| Amortization of acquired intangible assets | 14 | |||||||
| Total Expenses | 297,679 | 289,248 | ||||||
| Operating Income | 92,978 | 109,883 | ||||||
| Other Income, net: | ||||||||
| Interest income | 11,090 | 10,735 | ||||||
| Interest expense | (5,952 | ) | ||||||
| Other income, net | 771 | 2,053 | ||||||
| Total Other Income, net | 11,861 | 6,836 | ||||||
| Income Before Income Taxes | 104,839 | 116,719 | ||||||
| Income Tax Provision | 17,741 | 22,061 | ||||||
| Net Income From Continuing Operations | 87,098 | 94,658 | ||||||
| Loss From Discontinued Operations Net of Tax | (3,300 | ) | ||||||
| Net Income GAAP | $ | 87,098 | $ | 91,358 | ||||
| GAAP Earnings Per Ordinary Share - Basic: | ||||||||
| From continuing operations | $ | 0.53 | $ | 0.56 | ||||
| From discontinued operations | $ | $ | (0.02 | ) | ||||
| From net income | $ | 0.53 | $ | 0.54 | ||||
| GAAP Earnings Per Ordinary Share - Diluted: | ||||||||
| From continuing operations | $ | 0.52 | $ | 0.55 | ||||
| From discontinued operations | $ | $ | (0.02 | ) | ||||
| From net income | $ | 0.52 | $ | 0.53 | ||||
| Weighted Average Number of Ordinary Shares Outstanding: | ||||||||
| Basic | 164,959 | 168,321 | ||||||
| Diluted | 168,357 | 170,977 | ||||||
| An itemized reconciliation between net income from continuing operations on a GAAP basis and Adjusted EBITDA is as follows: | ||||||||
| Net Income from Continuing Operations | $ | 87,098 | $ | 94,658 | ||||
| Adjustments: | ||||||||
| Depreciation and amortization expense | 7,818 | 6,658 | ||||||
| Interest income | (11,090 | ) | (10,735 | ) | ||||
| Interest expense | 5,952 | |||||||
| Income tax provision | 17,741 | 22,061 | ||||||
| EBITDA from Continuing Operations | 101,567 | 118,594 | ||||||
| EBITDA from Discontinued Operations | (3,913 | ) | ||||||
| EBITDA | 101,567 | 114,681 | ||||||
| Share-based compensation | 24,966 | 20,601 | ||||||
| Adjusted EBITDA | $ | 126,533 | $ | 135,282 |
| Alkermes plc and Subsidiaries | ||||||||
| Selected Financial Information (Unaudited) | ||||||||
| Condensed Consolidated Statements of Operations - GAAP | Six Months Ended | Six Months Ended | ||||||
| (In thousands, except per share data) | June 30, 2025 | June 30, 2024 | ||||||
| Revenues: | ||||||||
| Product sales, net | $ | 551,728 | $ | 502,809 | ||||
| Manufacturing and royalty revenues | 145,439 | 246,691 | ||||||
| Research and development revenue | 3 | |||||||
| Total Revenues | 697,167 | 749,503 | ||||||
| Expenses: | ||||||||
| Cost of goods manufactured and sold | 98,657 | 120,116 | ||||||
| Research and development | 149,187 | 127,260 | ||||||
| Selling, general and administrative | 342,553 | 347,862 | ||||||
| Amortization of acquired intangible assets | 1,073 | |||||||
| Total Expenses | 590,397 | 596,311 | ||||||
| Operating Income | 106,770 | 153,192 | ||||||
| Other Income, net: | ||||||||
| Interest income | 21,231 | 20,134 | ||||||
| Interest expense | (11,930 | ) | ||||||
| Other income, net | 2,327 | 2,235 | ||||||
| Total Other Income, net | 23,558 | 10,439 | ||||||
| Income Before Income Taxes | 130,328 | 163,631 | ||||||
| Income Tax Provision | 20,766 | 30,025 | ||||||
| Net Income From Continuing Operations | 109,562 | 133,606 | ||||||
| Loss From Discontinued Operations Net of Tax | (5,420 | ) | ||||||
| Net Income GAAP | $ | 109,562 | $ | 128,186 | ||||
| GAAP Earnings Per Ordinary Share - Basic: | ||||||||
| From continuing operations | $ | 0.67 | $ | 0.79 | ||||
| From discontinued operations | $ | $ | (0.03 | ) | ||||
| From net income | $ | 0.67 | $ | 0.76 | ||||
| GAAP Earnings Per Ordinary Share - Diluted: | ||||||||
| From continuing operations | $ | 0.65 | $ | 0.78 | ||||
| From discontinued operations | $ | $ | (0.03 | ) | ||||
| From net income | $ | 0.65 | $ | 0.75 | ||||
| Weighted Average Number of Ordinary Shares Outstanding: | ||||||||
| Basic | 164,188 | 168,152 | ||||||
| Diluted | 168,470 | 171,960 | ||||||
| An itemized reconciliation between net income from continuing operations on a GAAP basis and Adjusted EBITDA is as follows: | ||||||||
| Net Income from Continuing Operations | $ | 109,562 | $ | 133,606 | ||||
| Adjustments: | ||||||||
| Depreciation and amortization expense | 15,239 | 14,714 | ||||||
| Interest income | (21,231 | ) | (20,134 | ) | ||||
| Interest expense | 11,930 | |||||||
| Income tax provision | 20,766 | 30,025 | ||||||
| EBITDA from Continuing Operations | 124,336 | 170,141 | ||||||
| EBITDA from Discontinued Operations | (6,429 | ) | ||||||
| EBITDA | 124,336 | 163,712 | ||||||
| Share-based compensation | 47,776 | 53,356 | ||||||
| Adjusted EBITDA | $ | 172,112 | $ | 217,068 |
| Alkermes plc and Subsidiaries | ||||||||
| Selected Financial Information (Unaudited) | ||||||||
| Condensed Consolidated Balance Sheets | June 30, | December 31, | ||||||
| (In thousands) | 2025 | 2024 | ||||||
| Cash, cash equivalents and total investments | $ | 1,054,008 | $ | 824,816 | ||||
| Receivables | 354,906 | 389,733 | ||||||
| Inventory | 191,924 | 182,887 | ||||||
| Contract assets | 1,424 | 4,990 | ||||||
| Prepaid expenses and other current assets | 71,295 | 86,077 | ||||||
| Property, plant and equipment, net | 239,399 | 227,564 | ||||||
| Intangible assets, net and goodwill | 83,880 | 83,917 | ||||||
| Deferred tax assets | 155,533 | 154,835 | ||||||
| Other assets | 100,440 | 100,748 | ||||||
| Total Assets | $ | 2,252,809 | $ | 2,055,567 | ||||
| Accrued sales discounts, allowances and reserves | $ | 253,173 | $ | 272,452 | ||||
| Other current liabilities | 252,789 | 192,747 | ||||||
| Other long-term liabilities | 122,263 | 125,391 | ||||||
| Total shareholders' equity | 1,624,584 | 1,464,977 | ||||||
| Total Liabilities and Shareholders' Equity | $ | 2,252,809 | $ | 2,055,567 | ||||
| Ordinary shares outstanding (in thousands) | 165,055 | 162,177 | ||||||
| This selected financial information should be read in conjunction with the consolidated financial statements and notes thereto included in Alkermes plc's Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, which the company intends to file in July 2025. |